1. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. (26th February 2018) Authors: Sydes, M R; Spears, M R; Mason, M D; Clarke, N W; Dearnaley, D P; de Bono, J S; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, Z I; Jones, R; Parker, C C; Ritchie, A W S; Russell, J M; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. (27th September 2019) Authors: Clarke, N W; Ali, A; Ingleby, F C; Hoyle, A; Amos, C L; Attard, G; Brawley, C D; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, D P; Douis, H; Gilbert, D; Gillessen, S; Jones, R J; Langley, R E; MacNair, A; Malik, Z; Mason, M D Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1992 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗